Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 865870, 17 pages
http://dx.doi.org/10.1155/2011/865870
Review Article

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Department of Haematology, Royal Free Hospital, Pond Street, London NW3 2TB, UK

Received 3 August 2010; Accepted 15 November 2010

Academic Editor: Myriam Labopin

Copyright © 2011 S. E. Richardson and C. McNamara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hasenclever and V. Diehl, “A prognostic score for advanced Hodgkin's disease,” New England Journal of Medicine, vol. 339, no. 21, pp. 1506–1514, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Henry-Amar, D. M. Aeppli, J. Anderson et al., “Long term survival and study of causes of death,” in Treatment Strategy in Hodgkin’s Disease, R. Somers, M. Henry-Amar, J. K. Meerwaldt, and P. Carde, Eds., pp. 381–418, John Libbey and Co, London, UK, 1990. View at Google Scholar
  3. O. W. Press, M. LeBlanc, A. S. Lichter et al., “Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease,” Journal of Clinical Oncology, vol. 19, no. 22, pp. 4238–4244, 2001. View at Google Scholar · View at Scopus
  4. A. Engert, J. Franklin, H. T. Eich et al., “Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3495–3502, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. E. M. Noordijk, P. Carde, N. Dupouy et al., “Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3128–3135, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. C. Fermé, H. Eghbali, J. H. Meerwaldt et al., “Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease,” New England Journal of Medicine, vol. 357, no. 19, pp. 1916–1927, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa, “ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2835–2841, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. R. M. Meyer, M. K. Gospodarowicz, J. M. Connors et al., “Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4634–4642, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. J. Straus, C. S. Portlock, J. Qin et al., “Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease,” Blood, vol. 104, no. 12, pp. 3483–3489, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. C. Herbst, F. A. Rehan, C. Brillant et al., “Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review,” Haematologica, vol. 95, no. 3, pp. 494–500, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Engert, A. Plütschow, H. T. Eich et al., “Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma,” New England Journal of Medicine, vol. 363, no. 7, pp. 640–652, 2010. View at Publisher · View at Google Scholar · View at PubMed
  12. P. Carde, A. Hagenbeek, M. Hayat et al., “Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group,” Journal of Clinical Oncology, vol. 11, no. 11, pp. 2258–2272, 1993. View at Google Scholar · View at Scopus
  13. A. Engert, P. Schiller, A. Josting et al., “Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group,” Journal of Clinical Oncology, vol. 21, no. 19, pp. 3601–3608, 2003. View at Publisher · View at Google Scholar · View at PubMed
  14. D. L. Longo, R. C. Young, and M. Wesley, “Twenty years of MOPP therapy for Hodgkin's disease,” Journal of Clinical Oncology, vol. 4, no. 9, pp. 1295–1306, 1986. View at Google Scholar · View at Scopus
  15. G. Bonadonna, P. Valagussa, and A. Santoro, “Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results,” Annals of Internal Medicine, vol. 104, no. 6, pp. 739–746, 1986. View at Google Scholar · View at Scopus
  16. G. P. Canellos, J. R. Anderson, K. J. Propert et al., “Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD,” New England Journal of Medicine, vol. 327, no. 21, pp. 1478–1484, 1992. View at Google Scholar · View at Scopus
  17. S. Viviani, G. Bonadonna, A. Santoro et al., “Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1421–1430, 1996. View at Google Scholar · View at Scopus
  18. J. M. Connors, P. Klimo, G. Adams et al., “Treatment of advanced Hodgkin's disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1638–1645, 1997. View at Google Scholar
  19. D. B. Duggan, G. R. Petroni, J. L. Johnson et al., “Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial,” Journal of Clinical Oncology, vol. 21, no. 4, pp. 607–614, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Diehl, M. Sieber, U. Rüffer et al., “BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease,” Annals of Oncology, vol. 8, no. 2, pp. 143–148, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Diehl, J. Franklin, M. Pfreundschuh et al., “Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease,” New England Journal of Medicine, vol. 348, no. 24, pp. 2386–2395, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. A. Engert, V. Diehl, J. Franklin et al., “Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4548–4554, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. V. Ballova, J. U. Rüffer, H. Haverkamp et al., “A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9),” Annals of Oncology, vol. 16, no. 1, pp. 124–131, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. Federico, S. Luminari, E. Iannitto et al., “ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced hodgkin's lymphoma: results from the HD2000 gruppo italiano Per lo studio dei linfomi trial,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 805–811, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. V. Diehl, H. Haverkamp, R. P. Mueller et al., “Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HL): final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG),” Blood, vol. 112, abstract 1558, 2008. View at Google Scholar
  26. A. M. Gianni, A. Rambaldi, P. Zinzami et al., “Comparable 3 year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomised trial of the Michelangelo, GITIL and IIL cooperative groups,” Journal of Clinical Oncology, vol. 26, abstract 8506, 2008. View at Google Scholar
  27. M. Sieber, H. Bredenfeld, A. Josting et al., “14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group,” Journal of Clinical Oncology, vol. 21, no. 9, pp. 1734–1739, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. J. Horning, R. T. Hoppe, S. Breslin, N. L. Bartlett, B. William Brown, and S. A. Rosenberg, “Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 630–637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Horning, J. Williams, N. L. Bartlett et al., “Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492,” Journal of Clinical Oncology, vol. 18, no. 5, pp. 972–980, 2000. View at Google Scholar · View at Scopus
  30. P. G. Gobbi, A. Levis, T. Chisesi et al., “ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9198–9207, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. P. J. Hoskin, L. Lowry, A. Horwich et al., “Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5390–5396, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. P. W. M. Johnson, J. A. Radford, M. H. Cullen et al., “Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9208–9218, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. B. M. P. Aleman, J. M. M. Raemaekers, R. Tomisic et al., “Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 1, pp. 19–30, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. C. Fermé, N. Mounier, O. Casasnovas et al., “Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Blood, vol. 107, no. 12, pp. 4636–4642, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. C. Kobe, M. Dietlein, J. Franklin et al., “Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma,” Blood, vol. 112, no. 10, pp. 3989–3994, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. Loeffler, O. Brosteanu, D. Hasenclever et al., “Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease,” Journal of Clinical Oncology, vol. 16, no. 3, pp. 818–829, 1998. View at Google Scholar
  37. T. Terasawa, J. Lau, S. Bardet et al., “Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1906–1914, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. J. Proctor, M. Mackie, A. Dawson et al., “A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III),” European Journal of Cancer, vol. 38, no. 6, pp. 795–806, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Federico, M. Bellei, P. Brice et al., “High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2320–2325, 2003. View at Publisher · View at Google Scholar · View at PubMed
  40. D. C. Hodgson, M. Pintilie, L. Gitterman et al., “Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy,” Hematological Oncology, vol. 25, no. 1, pp. 11–15, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. A. E. Van Der Kaaij, N. Heutte, N. Le Stang et al., “Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2825–2832, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. Sieniawski, T. Reineke, L. Nogova et al., “Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG),” Blood, vol. 111, no. 1, pp. 71–76, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. K. Behringer, L. Wildt, H. Mueller et al., “No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group,” Annals of Oncology, vol. 21, no. 10, pp. 2052–2060, 2010. View at Publisher · View at Google Scholar · View at PubMed
  44. G. P. Canellos, D. Duggan, J. Johnson, and D. Niedzwiecki, “How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1532–1533, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. Gallamini, M. Hutchings, L. Rigacci et al., “Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3746–3752, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. E. J. Dann, R. Bar-Shalom, A. Tamir et al., “Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome,” Blood, vol. 109, no. 3, pp. 905–909, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. M. Ansell and J. O. Armitage, “Management of Hodgkin lymphoma,” Mayo Clinic Proceedings, vol. 81, no. 3, pp. 419–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. D. L. Longo, P. L. Duffey, R. C. Young et al., “Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure,” Journal of Clinical Oncology, vol. 10, no. 2, pp. 210–218, 1992. View at Google Scholar · View at Scopus
  49. V. Bonfante, A. Santoro, S. Viviani et al., “Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 528–534, 1997. View at Google Scholar · View at Scopus
  50. D. C. Linch, D. Winfield, A. H. Goldstone et al., “Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial,” Lancet, vol. 341, no. 8852, pp. 1051–1054, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Schmitz, B. Pfistner, M. Sextro et al., “Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial,” Lancet, vol. 359, no. 9323, pp. 2065–2071, 2002. View at Publisher · View at Google Scholar · View at PubMed
  52. A. K. Gopal, T. L. Metcalfe, T. A. Gooley et al., “High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma the seattle experience,” Cancer, vol. 113, no. 6, pp. 1344–1350, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. P. Brice, M. Divine, D. Simon et al., “Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD),” Annals of Oncology, vol. 10, no. 12, pp. 1485–1488, 1999. View at Publisher · View at Google Scholar
  54. F. Morschhauser, P. Brice, C. Fermé et al., “Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5980–5987, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. Josting, C. Rudolph, M. Mapara et al., “Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG),” Annals of Oncology, vol. 16, no. 1, pp. 116–123, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. A. Josting, C. Rudolph, M. Reiser et al., “Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease,” Annals of Oncology, vol. 13, no. 10, pp. 1628–1635, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. Moskowitz, S. D. Nimer, A. D. Zelenetz et al., “A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model,” Blood, vol. 97, no. 3, pp. 616–623, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. S. J. Proctor, G. H. Jackson, A. Lennard et al., “Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK),” Annals of Oncology, vol. 14, no. 1, pp. i47–i50, 2003. View at Google Scholar · View at Scopus
  59. A. Martín, M. C. Fernández-Jiménez, M. D. Caballero et al., “Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease,” British Journal of Haematology, vol. 113, no. 1, pp. 161–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Bonfante, S. Viviani, L. Devizzi et al., “High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease,” European Journal of Haematology, Supplement, vol. 61, no. 64, pp. 51–55, 2001. View at Google Scholar · View at Scopus
  61. V. Bonfante, S. Viviani, A. Santoro et al., “Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease,” British Journal of Haematology, vol. 103, no. 2, pp. 533–535, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Ferme, Y. Bastion, E. Lepage et al., “The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease,” Annals of Oncology, vol. 6, no. 6, pp. 543–549, 1995. View at Google Scholar · View at Scopus
  63. J. Rodriguez, M. A. Rodriguez, L. Fayad et al., “ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease,” Blood, vol. 93, no. 11, pp. 3632–3636, 1999. View at Google Scholar · View at Scopus
  64. N. L. Bartlett, D. Niedzwiecki, J. L. Johnson et al., “Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804,” Annals of Oncology, vol. 18, no. 6, pp. 1071–1079, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. T. Baetz, A. Belch, S. Couban et al., “Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group,” Annals of Oncology, vol. 14, no. 12, pp. 1762–1767, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. M. G. Pfreundschuh, U. Rueffer, B. Lathan et al., “Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's disease study group,” Journal of Clinical Oncology, vol. 12, no. 3, pp. 580–586, 1994. View at Google Scholar · View at Scopus
  67. A. Josting, L. Nogová, J. Franklin et al., “Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1522–1529, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. J. L. Gajewski, G. L. Phillips, K. A. Sobocinski et al., “Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 572–578, 1996. View at Google Scholar · View at Scopus
  69. N. Milpied, A. K. Fielding, R. M. Pearce, P. Ernst, and A. H. Goldstone, “Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease,” Journal of Clinical Oncology, vol. 14, no. 4, pp. 1291–1296, 1996. View at Google Scholar
  70. J. E. Anderson, M. R. Litzow, F. R. Appelbaum et al., “Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience,” Journal of Clinical Oncology, vol. 11, no. 12, pp. 2342–2350, 1993. View at Google Scholar · View at Scopus
  71. G. Akpek, R. F. Ambinder, S. Piantadosi et al., “Long-term results of blood and marrow transplantation for Hodgkin's Lymphoma,” Journal of Clinical Oncology, vol. 19, no. 23, pp. 4314–4321, 2001. View at Google Scholar · View at Scopus
  72. A. J. Peniket, M. C. Ruiz de Elvira, G. Taghipour et al., “An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation,” Bone Marrow Transplantation, vol. 31, no. 8, pp. 667–678, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. K. S. Peggs and S. Mackinnon, “Exploiting graft-versus-tumour responses using donor leukocyte infusions,” Best Practice and Research: Clinical Haematology, vol. 14, no. 4, pp. 723–739, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. S. P. Robinson, A. H. Goldstone, S. Mackinnon et al., “Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation,” Blood, vol. 100, no. 13, pp. 4310–4316, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. K. S. Peggs, A. Hunter, R. Chopra et al., “Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation,” Lancet, vol. 365, no. 9475, pp. 1934–1941, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. I. Alvarez, A. Sureda, M. D. Caballero et al., “Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol,” Biology of Blood and Marrow Transplantation, vol. 12, no. 2, pp. 172–183, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. P. Anderlini, R. Saliba, S. Acholonu et al., “Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience,” Haematologica, vol. 93, no. 2, pp. 257–264, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. A. Sureda, S. Robinson, C. Canals et al., “Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 455–462, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. P. Anderlini, S. A. Acholonu, G. J. Okoroji et al., “Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response,” Bone Marrow Transplantation, vol. 34, no. 6, pp. 511–514, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. K. S. Peggs, A. Sureda, W. Qian et al., “Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes,” British Journal of Haematology, vol. 139, no. 1, pp. 70–80, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. K. J. Thomson, K. S. Peggs, P. Smith et al., “Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation,” Bone Marrow Transplantation, vol. 41, no. 9, pp. 765–770, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. A. J. Moskowitz, J. Yahalom, T. Kewalramani et al., “Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma,” Blood, vol. 116, no. 23, pp. 4934–4937, 2010. View at Publisher · View at Google Scholar · View at PubMed
  83. A. Forero-Torres, J. P. Leonard, A. Younes et al., “A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma,” British Journal of Haematology, vol. 146, no. 2, pp. 171–179, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. S. M. Ansell, S. M. Horwitz, A. Engert et al., “Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2764–2769, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. A. Younes, A. Forero-Torres, N. L. Bartlett et al., “Multiple complete responses in a phase I dose escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas,” Blood, vol. 112, abstract 1006, 2008. View at Google Scholar
  86. N. Bartlett, A. Forero-Torrres, J. Rosenblatt et al., “Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL),” in Proceedings of the American Society of Clinical Oncology (ASCO '09), vol. 27, abstract 8500, 2009.
  87. G. Dancey, J. Violet, A. Malaroda et al., “A phase I clinical trial of CHT-25 a I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma,” Clinical Cancer Research, vol. 15, no. 24, pp. 7701–7710, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. A. Younes, A. Wedgwood, P. McLaughlin et al., “Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study,” Blood, vol. 110, abstract 2571, 2007. View at Google Scholar
  89. M. Dickinson, D. Ritchie, D. J. Deangelo et al., “Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma,” British Journal of Haematology, vol. 147, no. 1, pp. 97–101, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. A. Younes, A. Sureda, D. ben-Yehuda et al., “Phase II study of oral panobinostat in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant (ASCT),” Haematologica, vol. 94, abstract 34, 2009. View at Google Scholar
  91. M. H. Kirschbaum, B. H. Goldman, J. M. Zain et al., “Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517,” Blood, vol. 110, abstract 2574, 2007. View at Google Scholar
  92. P. B. Johnston, D. J. Inwards, J. P. Colgan et al., “A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma,” American Journal of Hematology, vol. 85, no. 5, pp. 320–324, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. B. Zheng, G. V. Georgakis, Y. Li et al., “Induction of cell cycle arrest and apoptosis by the proteosome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors,” Clinical Cancer Research, vol. 10, no. 9, pp. 3207–3215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Böll, H. Hansen, F. Heuck et al., “The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis,” Blood, vol. 106, no. 5, pp. 1839–1842, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. A. Younes, B. Pro, and L. Fayad, “Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma,” Blood, vol. 107, no. 4, pp. 1731–1732, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. K. A. Blum, J. L. Johnson, D. Niedzwiecki, G. P. Canellos, B. D. Cheson, and N. L. Bartlett, “Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206,” Leukemia and Lymphoma, vol. 48, no. 7, pp. 1313–1319, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. A. Younes, J. Romaguera, F. Hagemeister et al., “A pilot study of rituximab in patients with recurrent, classic Hodgkin disease,” Cancer, vol. 98, no. 2, pp. 310–314, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. U. Rehwald, H. Schulz, M. Reiser et al., “Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group,” Blood, vol. 101, no. 2, pp. 420–424, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. A. R. Wedgewood, M. A. Fanale, L. E. Fayad et al., “Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy,” Blood, vol. 110, abstract 215, 2007. View at Google Scholar
  100. Y. Oki, B. Pro, L. E. Fayad et al., “Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma,” Cancer, vol. 112, no. 4, pp. 831–836, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. B. Böll, P. Borchmann, M. S. Topp et al., “Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma,” British Journal of Haematology, vol. 148, no. 3, pp. 480–482, 2010. View at Publisher · View at Google Scholar · View at PubMed
  102. J. Kuruvilla, D. Taylor, L. Wang, C. Blatter, A. Keating, and M. Crump, “Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma,” Blood, vol. 112, 2008, abstract no. 3052. View at Google Scholar